[go: up one dir, main page]

US20120083534A1 - Ophthalmic and contact lens solution - Google Patents

Ophthalmic and contact lens solution Download PDF

Info

Publication number
US20120083534A1
US20120083534A1 US13/327,295 US201113327295A US2012083534A1 US 20120083534 A1 US20120083534 A1 US 20120083534A1 US 201113327295 A US201113327295 A US 201113327295A US 2012083534 A1 US2012083534 A1 US 2012083534A1
Authority
US
United States
Prior art keywords
peg
castor oil
glyceryl
buffer
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/327,295
Inventor
Francis X. Smith
John Randall Tracey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US13/327,295 priority Critical patent/US20120083534A1/en
Publication of US20120083534A1 publication Critical patent/US20120083534A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S134/00—Cleaning and liquid contact with solids
    • Y10S134/901—Contact lens

Definitions

  • the present invention relates to novel ophthalmic solutions that contain a ethoxylated glyceride as an additive to improve the wettability and to decrease the degree of protein and polymeric preservative binding to contact lens surfaces.
  • These compositions may also comprise other agents in contact lens and ophthalmic solutions such as buffers, tonicity agents, wetting agents, enzymes, hydrogen peroxide, demulcents, thickeners, sequestering agents (chelating agents), surface active agents and preservative agents.
  • the ethoxylated glycerides are particularly useful in contact lens treatment solutions, contact lens wetting solutions, solutions used to store contact lenses and solutions used to clean or rinse contact lenses.
  • ethoxylated glycerides improve the comfort of lenses treated with such solution and that this increased comfort is surprisingly long-lasting in its effect.
  • the ethoxylated glycerides maybe mono-, di- or triglycerides;
  • the solutions of the present invention are made by one of two methods.
  • First the ethoxylated glyceride may be melted and added to an aqueous solution which includes the other agents to be used in the desired formulation, or the additional agents may be added prior to the addition of the melted ethoxylated glyceride.
  • Second, the ethoxylated glyceride may be dissolved in an alcohol base and this liquid mixture, added to the aqueous base.
  • Ethoxylated glycerides are commercially available from numerous commercial sources and include Polyoxyl 40 hydrogenated castor oil (Cremophor RH 40), polyoxyl 60 hydrogenated castor oil (Cremophor RH 60), PEG-30 Castor Oil (Incrocas 30), PEG-35 Castor Oil (Cremophor EL, Incrocas 35), or PEG-40 Castor Oil (Cremophor EL, Incrocas), Cremophor EL®, Emulphor EL®, glycerol polyethyleneglycol riciinoleate, gycerol polyethyleneglycol oxystearate, polyethoxylated hydrogenated castor oil, or polyethoxylated vegetable oil.
  • Cremophor EL® Cremophor EL®, Emulphor EL®, glycerol polyethyleneglycol riciinoleate, gycerol polyethyleneglycol oxystearate, polyethoxylated hydrogenated castor oil, or poly
  • the ethoxylated glycerides useful in the present invention may include surfactants sold as PEG-6 Caprylic/Capric Glycerides PEG-8 Caprylic/Capric Glycerides; PEG-2 Castor Oil; PEG-3 Castor Oil; PEG-4 Castor Oil; PEG-5 Castor Oil; PEG-8 Castor Oil; PEG-9 Castor Oil; PEG-10 Castor Oil; PEG-11 Castor Oil; PEG-15 Castor Oil; PEG-20 Castor Oil; PEG-25 Castor Oil; PEG-30 Castor Oil; PEG-33 Castor Oil; PEG-35 Castor Oil; PEG-36 Castor Oil; PEG-40 Castor Oil; PEG-50 Castor Oil; PEG-54 Castor Oil; PEG-55 Castor Oil; PEG-60 Castor Oil; PEG-100 Castor Oil; PEG-200 Castor Oil; PEG-18 Castor Oil Dioleate; PEG-60 Corn Glycerides; PEG-20 Evening Primrose Glycerides;
  • PEG-60 Evening Primrose Glycerides; PEG-7 Glyceryl Cocoate; PEG-30 Glyceryl Cocoate; PEG-78 Glyceryl Cocoate; PEG-80 Glyceryl Cocoate; PEG-12 Glyceryl Dioleate; PEG-15 Glyceryl Isostearate; PEG-20 Glyceryl Isostearate; PEG-30 Glyceryl Isostearate; PEG-60 Glyceryl Isostearate; PEG-12 Glyceryl Laurate; PEG-20 Glyceryl Laurate; PEG-23 Glyceryl Laurate; PEG-30 Glyceryl Laurate; PEG-10 Glyceryl Oleate; PEG-15 Glyceryl Oleate; PEG-30 Glyceryl Oleate; PEG-20 Glyceryl Ricinoleate; PEG-5 Glyceryl Sesquioleate; PEG-S Glyceryl Stearate; PEG-10 Glyceryl Stearate; PEG-25 Glyceryl Stea
  • solutions of the present invention may contain other additives including but not limited to buffers, tonicity agents, demulcents, wetting agents, preservatives, sequestering agents (chelating agents), surface active agents, and enzymes.
  • chelating agent preferably disodium EDTA
  • additional microbicide preferably 0.00001 to 0.1 or 0.00001 to 0.01
  • PHMBO polyhexamethylene biquanide
  • chlorhexidine polyquatemium-1, hexetidine, bronopol, alexidine
  • low concentrations of hydrogen peroxide and ophthalmologically acceptable salts thereof
  • Ophthalmologically acceptable chelating agents useful in the present invention include amino carboxylic acid compounds or water-soluble salts thereof, including ethylenediaminetetraacetic acid, nitrilotriacetic acid, diethylenetriamine pentaacetic acid, hydroxyethylethylenediaminetriacetic acid, 1,2-diaminocyclohexanetetraacetic acid, ethylene glycol his (beta-aminoethyl ether) in N,N,N′,N′ tetraacetic acid (EGTA), aminodiacetic acid and hydroxyethylamino diacetic acid.
  • These acids can be used in the form of their water soluble salts, particularly their alkali metal salts.
  • Especially preferred chelating agents are the di-, tri- and tetra-sodium salts of ethylenediaminetetraacetic acid (EDTA), most preferably disodium EDTA (Disodium Edetate).
  • citrates and polyphosphates can also be used in the present invention.
  • the citrates which can be used in the present invention include citric acid and its mono-, di-, and tri-alkaline metal salts.
  • the polyphosphates which can be used include pyrophosphates, triphosphates, tetraphosphates, trimetaphosphates, tetrametaphosphates, as well as more highly condensed phosphates in the form of the neutral or acidic alkali metal salts such as the sodium and potassium salts as well as the ammonium salt.
  • the pH of the solutions should be adjusted to be compatible with the eye and the contact lens, such as between 6.0 to 8.0, preferably between 6.8 to 7.8 or between 7.0 to 7.6. Significant deviations from neutral (pH 7.3) will cause changes in the physical parameters (i.e. diameter) in some contact lenses. Low pH (pH less than 5.5) can cause burning and stinging of the eyes, while very low or very high pH (less than 3.0 or greater than 10) can cause ocular damage.
  • the additional preservatives employed in the present invention are known, such as polyhexamethylene biguanide, N-alkyl-2-pyrrolidone, chlorhexidine, polyhexamethylenebiguanide, alexidine, polyquatemium-1, hexetidine, bronopol and a very low concentration of hydrogen peroxide, e.g., 30 to 200 rpm.
  • solutions of the invention are compatible with both rigid gas permeable and hydrophilic contact lenses during storage, cleaning, wetting, soaking, rinsing and disinfection.
  • a typical aqueous solution of the present invention may contain additional ingredients which would not affect the basic and novel characteristics of the active ingredients described earlier, such as tonicity agents, surfactants and viscosity inducing agents, which may aid in either the lens cleaning or in providing lubrication to the eye.
  • Suitable tonicity agents include sodium chloride, potassium chloride, glycerol or mixtures thereof.
  • the tonicity of the solution is typically adjusted to approximately 240-310 milliosmoles per kilogram solution (mOsm/kg) to render the solution compatible with ocular tissue and with hydrophilic contact lenses. In one embodiment, the solution contains 0.01 to 0.5 weight percent sodium chloride.
  • Suitable viscosity inducing agents can include lecithin or the cellulose derivatives such as hydroxymethylcellulose, hydroxypropylcellulose and methylcellulose in amounts similar to those for surfactants, above.
  • Hydrophilic contact lenses were placed flat onto glass slides and rinsed with water to remove any debris. These slides were placed in a petri dish and covered with a few drops of each of the test solutions previously prepared in either water, an aqueous isotonic sodium chloride solution, or an aqueous phosphate buffered solution made isotonic with sodium chloride and adjusted to pH 7.3. Each petri plate was covered and placed in a refrigerator overnight. The following day, the slides were removed and allowed to equilibrate to room temperature. The lenses were rinsed with water and the excess water was removed. One 5 uL drop of mineral oil stained with Oil Red 0 was placed onto one lens for each solution. After ten minutes, the lenses were observed for the ability of the oil drop to spread.
  • the results demonstrates that exposure of the contact lens to the ethoxylated glyceride will generate a durable modified surface capable of allow the formation of a thin oil and aqueous film. This characteristic mimics mucin and is essential for the proper tear layer formation of over the lens. A score of 3 or better is considered acceptable.
  • This experiment also illustrates the synergistic improvement when the ethoxylated glyceride is exposed in the presence of a buffer.
  • the inability of the Poloxamer and Poloxamine to allow the oil film to spread across the lens demonstrates that not all surface active agents will promote the spreading of a properly formed tear film over the contact lens, surface.
  • Lens A Lens B Average ug/lens ug/lens ug/lens Phosphate buffer control 1,043 865 954 Cremophor RH40 (1%) 15 23 19 In Phosphate Buffer
  • Ethoxylated Castor Oil was a 1 percent w/v solution.
  • the matrix control was phosphate buffer and sodium chloride.
  • the polyoxyl 40 hydrogenated castor oil solution had lower protein binding than the control.
  • Isotonic aqueous phosphate buffered solutions were prepared and adjusted to pH 7.4. Contact lenses were soaked in 25 mL of the test solutions overnight. Afterwards, lysozyme was added to the tubes and warmed to 37 degrees Celsius for 12 hours. The lenses were rinsed with distilled water in order to remove residual solution. The lenses were assayed for protein deposition by the RCA method and detected on an HP PDA Spectrophotometer. Results were reported in ug/lens.
  • Ethoxylated Castor Oil was a 1 percent w/v solution.
  • the matrix control was phosphate buffer and sodium chloride.
  • the polyoxyl 40 hydrogenated castor oil solution had lower protein binding than the control.
  • Table 1 An example of a preferred disinfecting formulation of the subject invention is provided below in Table 1.
  • This solution is prepared by weighing out the necessary amount of the tricine, creatine, choline chloride, sodium chloride and edetate disodium into a vessel containing approximately 90% of the water volume. After each of the ingredients has dissolved, the pH is adjusted to 7.3 with either 1 N sodium hydroxide or 1 N hydrochloric acid. Following this, the polyhexamethylene biguanide is added and the solution is brought to final volume with purified water. The final product has the composition shown in the Table below.
  • This solution may be used to rinse, clean, and store contact lenses on a daily basis.
  • Table I An example of a preferred formulation for a contact lens vial storage of the subject invention is provided below in Table I.
  • This solution is prepared by weighing out the necessary amount of the sodium borate, boric acid, and sodium chloride into a vessel containing approximately 90% of the water volume. After each of the ingredients has dissolved, the pH is adjusted to 7.3 with either 1 N sodium hydroxide or 1 N hydrochloric acid. The final product had the composition shown in Table I below.
  • the following are useful disinfecting solutions within the scope of the present invention that may be used for all purpose disinfecting solutions. They are made according to generally acceptable procedures except that the ethoxylated glycerides must be first be dissolved in warm water prior to the addition of the other components.
  • % Weight/ Constituent Supplier Volume Amount Purified Water to 80% 40 mL Tricine Spectrum 1.0% 0.500 g Carnitine Spectrum .25% 0.125 g Betaine HCl Spectrum 0.1% 0.050 g Choline Chloride Amresco 0.5% 0.250 g Inositol Spectrum 0.1% 0.050 g Edetate Disodium Spectrum 0.055% 0.0275 g Polyoxyl 40 Cremophor 0.1% 0.5 mL of 10% Hyrdogenated RH 40 from Castor Oil BASF Co.
  • % Weight/ Constituent Supplier Volume Amount Purified To 80% 40 mL Water Tricine Spectrum 1.0% 0.500 g Carnitine Spectrum 0.25% 0.125 g Inositol Spectrum 0.1% 0.050 g Hydrochloride As required for pH As required for pH Acid, 1N adjustment to 7.3% adjustment to 7.3% Sodium As required for pH As required for pH Hydroxide, adjustment to 7.3% adjustment to 7.3% 1N Polyoxyl 40 Cremophor 0.1% 0.5 mL of 10% Hydrogenated RH 40 from Castor Oil BASF Co. Purified Water To 98% Dilute to 49 mL Sodium Fisher As required for As required for Chloride tonicity adjustment tonicity adjustment 300 mOsm 300 mOsm Purified Water Too 100% Dilute to 50 mL

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Eyeglasses (AREA)

Abstract

An ophthalmic solution comprising a polyethoxylated glyceride in the range of 0.001 to about 10 percent by weight and a buffer agent. These solutions impart surprising comfort and wearability to contact lenses. At the same time the solutions provide good preservative capacity and do not increase protein deposit.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is continuation of and claims priority from U.S. patent application Ser. No. 12/693,878, filed Jan. 26, 2010 which is a continuation U.S. patent application Ser. No. 10/842,162, filed May 10, 2004, now U.S. Pat. No. 7,678,836 which is a continuation of U.S. patent application Ser. No. 09/706,338 filed Nov. 4, 2000 which claims priority from U.S. Provisional application Ser. No. 60/163,455 filed Nov. 4, 1999. The contents of which are incorporated in their entirety by reference.
    • BACKGROUND
  • The present invention relates to novel ophthalmic solutions that contain a ethoxylated glyceride as an additive to improve the wettability and to decrease the degree of protein and polymeric preservative binding to contact lens surfaces. These compositions may also comprise other agents in contact lens and ophthalmic solutions such as buffers, tonicity agents, wetting agents, enzymes, hydrogen peroxide, demulcents, thickeners, sequestering agents (chelating agents), surface active agents and preservative agents. The ethoxylated glycerides are particularly useful in contact lens treatment solutions, contact lens wetting solutions, solutions used to store contact lenses and solutions used to clean or rinse contact lenses. It has been found that surprisingly the addition of ethoxylated glycerides improve the comfort of lenses treated with such solution and that this increased comfort is surprisingly long-lasting in its effect. The ethoxylated glycerides maybe mono-, di- or triglycerides;
    • DETAILED DESCRIPTION
  • The solutions of the present invention are made by one of two methods. First the ethoxylated glyceride may be melted and added to an aqueous solution which includes the other agents to be used in the desired formulation, or the additional agents may be added prior to the addition of the melted ethoxylated glyceride. Second, the ethoxylated glyceride may be dissolved in an alcohol base and this liquid mixture, added to the aqueous base. Ethoxylated glycerides are commercially available from numerous commercial sources and include Polyoxyl 40 hydrogenated castor oil (Cremophor RH 40), polyoxyl 60 hydrogenated castor oil (Cremophor RH 60), PEG-30 Castor Oil (Incrocas 30), PEG-35 Castor Oil (Cremophor EL, Incrocas 35), or PEG-40 Castor Oil (Cremophor EL, Incrocas), Cremophor EL®, Emulphor EL®, glycerol polyethyleneglycol riciinoleate, gycerol polyethyleneglycol oxystearate, polyethoxylated hydrogenated castor oil, or polyethoxylated vegetable oil. The ethoxylated glycerides useful in the present invention may include surfactants sold as PEG-6 Caprylic/Capric Glycerides PEG-8 Caprylic/Capric Glycerides; PEG-2 Castor Oil; PEG-3 Castor Oil; PEG-4 Castor Oil; PEG-5 Castor Oil; PEG-8 Castor Oil; PEG-9 Castor Oil; PEG-10 Castor Oil; PEG-11 Castor Oil; PEG-15 Castor Oil; PEG-20 Castor Oil; PEG-25 Castor Oil; PEG-30 Castor Oil; PEG-33 Castor Oil; PEG-35 Castor Oil; PEG-36 Castor Oil; PEG-40 Castor Oil; PEG-50 Castor Oil; PEG-54 Castor Oil; PEG-55 Castor Oil; PEG-60 Castor Oil; PEG-100 Castor Oil; PEG-200 Castor Oil; PEG-18 Castor Oil Dioleate; PEG-60 Corn Glycerides; PEG-20 Evening Primrose Glycerides;
  • PEG-60 Evening Primrose Glycerides; PEG-7 Glyceryl Cocoate; PEG-30 Glyceryl Cocoate; PEG-78 Glyceryl Cocoate; PEG-80 Glyceryl Cocoate; PEG-12 Glyceryl Dioleate; PEG-15 Glyceryl Isostearate; PEG-20 Glyceryl Isostearate; PEG-30 Glyceryl Isostearate; PEG-60 Glyceryl Isostearate; PEG-12 Glyceryl Laurate; PEG-20 Glyceryl Laurate; PEG-23 Glyceryl Laurate; PEG-30 Glyceryl Laurate; PEG-10 Glyceryl Oleate; PEG-15 Glyceryl Oleate; PEG-30 Glyceryl Oleate; PEG-20 Glyceryl Ricinoleate; PEG-5 Glyceryl Sesquioleate; PEG-S Glyceryl Stearate; PEG-10 Glyceryl Stearate; PEG-25 Glyceryl Stearate; PEG-30 Glyceryl Stearate; PEG-120 Glyceryl Stearate; PEG-200 Glyceryl Stearate; PEG-28 Glyceryl Tallowate; PEG-80 Glyceryl Tallowate; PEG-200 Glyceryl Tallowate; PEG-S Glyceryl Triisostearate; PEG-5 Hydrogenated Castor Oil; PEG-7 Hydrogenated Castor Oil; PEG-16 Hydrogenated Castor Oil; PEG-20 Hydrogenated Castor Oil; PEG-25 Hydrogenate Castor Oil; PEG-30 Hydrogenate Castor Oil; PEG-35 Hydrogenate Castor Oil; PEG-40 Hydrogenate Castor Oil; PEG-45 Hydrogenate Castor Oil; PEG-50 Hydrogenate Castor Oil; PEG-54 Hydrogenate Castor Oil; PEG-55 Hydrogenate Castor Oil; PEG-60 Hydrogenate Castor Oil; PEG-80 Hydrogenate Castor Oil; PEG-100 Hydrogenate Castor Oil; PEG-200 Hydrogenate Castor Oil; PEG-40 Hydrogenated Castor Oil PCA Isosterate; PEG-5 Hydrogenated Corn Glycerides; and PEG-8 Hydrogenated Fish Glycerides; which are all available from known commercial sources
  • The solutions of the present invention may contain other additives including but not limited to buffers, tonicity agents, demulcents, wetting agents, preservatives, sequestering agents (chelating agents), surface active agents, and enzymes.
  • Other aspects of the claimed solutions include adding to the solution from 0.001 to 1 weight percent chelating agent (preferably disodium EDTA) and/or additional microbicide, (preferably 0.00001 to 0.1 or 0.00001 to 0.01) weight percent polyhexamethylene biquanide (PHMBO, N-alkyl-2-pyrrolidone, chlorhexidine, polyquatemium-1, hexetidine, bronopol, alexidine, low concentrations of hydrogen peroxide, and ophthalmologically acceptable salts thereof
  • Ophthalmologically acceptable chelating agents useful in the present invention include amino carboxylic acid compounds or water-soluble salts thereof, including ethylenediaminetetraacetic acid, nitrilotriacetic acid, diethylenetriamine pentaacetic acid, hydroxyethylethylenediaminetriacetic acid, 1,2-diaminocyclohexanetetraacetic acid, ethylene glycol his (beta-aminoethyl ether) in N,N,N′,N′ tetraacetic acid (EGTA), aminodiacetic acid and hydroxyethylamino diacetic acid. These acids can be used in the form of their water soluble salts, particularly their alkali metal salts. Especially preferred chelating agents are the di-, tri- and tetra-sodium salts of ethylenediaminetetraacetic acid (EDTA), most preferably disodium EDTA (Disodium Edetate).
  • Other chelating agents such as citrates and polyphosphates can also be used in the present invention. The citrates which can be used in the present invention include citric acid and its mono-, di-, and tri-alkaline metal salts. The polyphosphates which can be used include pyrophosphates, triphosphates, tetraphosphates, trimetaphosphates, tetrametaphosphates, as well as more highly condensed phosphates in the form of the neutral or acidic alkali metal salts such as the sodium and potassium salts as well as the ammonium salt.
  • The pH of the solutions should be adjusted to be compatible with the eye and the contact lens, such as between 6.0 to 8.0, preferably between 6.8 to 7.8 or between 7.0 to 7.6. Significant deviations from neutral (pH 7.3) will cause changes in the physical parameters (i.e. diameter) in some contact lenses. Low pH (pH less than 5.5) can cause burning and stinging of the eyes, while very low or very high pH (less than 3.0 or greater than 10) can cause ocular damage.
  • The additional preservatives employed in the present invention are known, such as polyhexamethylene biguanide, N-alkyl-2-pyrrolidone, chlorhexidine, polyhexamethylenebiguanide, alexidine, polyquatemium-1, hexetidine, bronopol and a very low concentration of hydrogen peroxide, e.g., 30 to 200 rpm.
  • The solutions of the invention are compatible with both rigid gas permeable and hydrophilic contact lenses during storage, cleaning, wetting, soaking, rinsing and disinfection.
  • A typical aqueous solution of the present invention may contain additional ingredients which would not affect the basic and novel characteristics of the active ingredients described earlier, such as tonicity agents, surfactants and viscosity inducing agents, which may aid in either the lens cleaning or in providing lubrication to the eye. Suitable tonicity agents include sodium chloride, potassium chloride, glycerol or mixtures thereof. The tonicity of the solution is typically adjusted to approximately 240-310 milliosmoles per kilogram solution (mOsm/kg) to render the solution compatible with ocular tissue and with hydrophilic contact lenses. In one embodiment, the solution contains 0.01 to 0.5 weight percent sodium chloride.
  • Suitable viscosity inducing agents can include lecithin or the cellulose derivatives such as hydroxymethylcellulose, hydroxypropylcellulose and methylcellulose in amounts similar to those for surfactants, above.
    • EXAMPLE 1
  • Hydrophilic contact lenses were placed flat onto glass slides and rinsed with water to remove any debris. These slides were placed in a petri dish and covered with a few drops of each of the test solutions previously prepared in either water, an aqueous isotonic sodium chloride solution, or an aqueous phosphate buffered solution made isotonic with sodium chloride and adjusted to pH 7.3. Each petri plate was covered and placed in a refrigerator overnight. The following day, the slides were removed and allowed to equilibrate to room temperature. The lenses were rinsed with water and the excess water was removed. One 5 uL drop of mineral oil stained with Oil Red 0 was placed onto one lens for each solution. After ten minutes, the lenses were observed for the ability of the oil drop to spread.
  • Oil Water
    Additive Solution Matrix Dispersibility Dispersibility
    1% polyoxyl 40 water 4 5
    hydrogenated castor oil
    (Cremophor RH 40)
    1% polyoxyl 40 buffer 5 5
    hydrogenated castor oil water
    (Cremophor RH 40)
    1% polyoxyl 40 sodium choride 2 5
    hydrogenated castor oil water
    (Crernophor RH 40)
    1% polyoxyl 40 buffer 3 5
    hydrogenated castor oil sodium chloride
    (Cremophor RH 40) water
    1% Polysorbate 80 sodium choride 4 5
    (Tween 80) water
    1% Poloxamine 1107 sodium choride 2 5
    (Tetronic 1107) water
    1% Poloxamer 407 sodium choride 2 5
    (Pluronic F127) water
    1% Polysorbate 80 buffer 3 5
    (Tween 80) sodium chloride
    water
    1% Poloxamine 1107 buffer 1 5
    (Tetronic 1107) sodium chloride
    water
    1% Poloxarner 407 buffer 1 5
    (Pluronic F127) sodium chloride
    water
    Water water 1 5
    Key
    1 non-spreading drop
    2 poor spreading drop
    3 moderate spreading drop
    4 increased spreading drop
    5 thin spreading film
  • The results demonstrates that exposure of the contact lens to the ethoxylated glyceride will generate a durable modified surface capable of allow the formation of a thin oil and aqueous film. This characteristic mimics mucin and is essential for the proper tear layer formation of over the lens. A score of 3 or better is considered acceptable. This experiment also illustrates the synergistic improvement when the ethoxylated glyceride is exposed in the presence of a buffer. The inability of the Poloxamer and Poloxamine to allow the oil film to spread across the lens demonstrates that not all surface active agents will promote the spreading of a properly formed tear film over the contact lens, surface.
    • EXAMPLE 2 Example of Protein Deposition Inhibition
  • Contact lenses were soaked and heated in test solutions to which a radio-labeled lysozyme was present in a known amount for a period of 12 hours at 37 degrees Celsius. The lenses were rinsed with distilled water in order to remove residual solution. The lenses were then assayed for protein deposition using a Beckman BioGamma 1 counter. Results were reported in ug/lens.
  • Lens A Lens B Average
    ug/lens ug/lens ug/lens
    Phosphate buffer control 1,043 865 954
    Cremophor RH40 (1%) 15 23 19
    In Phosphate Buffer
  • Ethoxylated Castor Oil was a 1 percent w/v solution. The matrix control was phosphate buffer and sodium chloride. The polyoxyl 40 hydrogenated castor oil solution had lower protein binding than the control.
    • EXAMPLE 3 Example of Protein Deposition Inhibition
  • Isotonic aqueous phosphate buffered solutions were prepared and adjusted to pH 7.4. Contact lenses were soaked in 25 mL of the test solutions overnight. Afterwards, lysozyme was added to the tubes and warmed to 37 degrees Celsius for 12 hours. The lenses were rinsed with distilled water in order to remove residual solution. The lenses were assayed for protein deposition by the RCA method and detected on an HP PDA Spectrophotometer. Results were reported in ug/lens.
  • Solution ug lysozyme per lens
    Marketed Product Control >18.3
    (phosphate buffer, Poloxamer)
    Phosphate buffer control >26.16
    Cremophor RH40 (1%) 9.78
    In Phosphate Buffer
  • Ethoxylated Castor Oil was a 1 percent w/v solution. The matrix control was phosphate buffer and sodium chloride. The polyoxyl 40 hydrogenated castor oil solution had lower protein binding than the control.
    • EXAMPLE 4
  • An example of a preferred disinfecting formulation of the subject invention is provided below in Table 1. This solution is prepared by weighing out the necessary amount of the tricine, creatine, choline chloride, sodium chloride and edetate disodium into a vessel containing approximately 90% of the water volume. After each of the ingredients has dissolved, the pH is adjusted to 7.3 with either 1 N sodium hydroxide or 1 N hydrochloric acid. Following this, the polyhexamethylene biguanide is added and the solution is brought to final volume with purified water. The final product has the composition shown in the Table below.
  • Weight/
    Constituent Volume
    Polyhexamethylenebiguanide 20% w/w solution 0.0001%
    HCl available under the mark
    Cosmocil CQ, from
    Avecia
    Tricine Spectrum   1.0%
    Creatine Spectrum  0.25%
    Choline Chloride Amersco   0.5%
    Edetate Disodium Spectrum  0.055%
    Polyoxyl 40 Hydrogenated Cremophor RH 40 from   0.1%
    Castor Oil BASF Co.
    Sodium Chloride Fisher Scientific As required for
    tonicity
    adjustment
    300 mOsm
    Hydrochloride Acid, IN VWR as required
    for pH adjust-
    ment to 7.3
    Sodium Hydroxide, 1N Mallinckrodt as required
    for pH adjust-
    ment to 7.3
    Purified Water Balance to
    100%
  • This solution may be used to rinse, clean, and store contact lenses on a daily basis.
    • EXAMPLE 5
  • An example of a preferred formulation for a contact lens vial storage of the subject invention is provided below in Table I. This solution is prepared by weighing out the necessary amount of the sodium borate, boric acid, and sodium chloride into a vessel containing approximately 90% of the water volume. After each of the ingredients has dissolved, the pH is adjusted to 7.3 with either 1 N sodium hydroxide or 1 N hydrochloric acid. The final product had the composition shown in Table I below.
  • Weight/
    Constituent Volume
    Sodium Borate Spectrum  1.0%
    Boric Acid Spectrum 0.25%
    Polyoxyl 40 Hydrogenated Cremophor RH40  0.1%
    Castor Oil from BASF
    Sodium Chloride Fisher Scientific As required for
    tonicity adjustment
    300 mOsm
    Hydrochloride Acid, 1N VWR as required for pH
    adjustment to 7.3
    Sodium Hydroxide, IN Mallinckrodt as required for pH
    adjustment to 7.3
    Purified Water Balance to 100%
    • EXAMPLE 6
  • The following are useful disinfecting solutions within the scope of the present invention that may be used for all purpose disinfecting solutions. They are made according to generally acceptable procedures except that the ethoxylated glycerides must be first be dissolved in warm water prior to the addition of the other components.
  • % Weight/
    Constituent Supplier Volume Amount
    Purified Water to 80% 40 mL
    Tricine Spectrum   1.0% 0.500 g
    Carnitine Spectrum   .25% 0.125 g
    Betaine HCl Spectrum   0.1% 0.050 g
    Choline Chloride Amresco   0.5% 0.250 g
    Inositol Spectrum   0.1% 0.050 g
    Edetate Disodium Spectrum  0.055% 0.0275 g
    Polyoxyl 40 Cremophor   0.1% 0.5 mL of 10%
    Hyrdogenated RH 40 from
    Castor Oil BASF Co.
    Hydrochloride As required for pH As required for pH
    Acid, 1N adjustment to 7.3 adjustment to 7.3
    Sodium As required for pH As required for pH
    Hydroxide, 1N adjustment to 7.3 adjustment to 7.3
    Purified Water To 98% Dilute to 49 mL
    Sodium Chloride Fisher As required for As required for
    tonicity tonicity
    adjustment adjustment
    300 mOsm 300 mOsm
    Polyhexameth- 20% w/w so- 0.0001% 50 uL of 0.1%
    ylene- lution avail-
    biguanide able under
    HCl the mark
    Cosmocil CQ
    from Avecia
    Purified Water Balance to 100% Dilute to 50 mL
    • EXAMPLE 7
  • The following are formulations within the scope of the invention of formulations intended to be used as lens-vial solutions that are used to store lenses prior to their use. These solutions have the effect of treating the contact lens in the solution and rendering the lens more comfortable in use.
  • % Weight/
    Constituent Supplier Volume Amount
    Purified To 80% 40 mL
    Water
    Tricine Spectrum  1.0% 0.500 g
    Carnitine Spectrum 0.25% 0.125 g
    Inositol Spectrum  0.1% 0.050 g
    Hydrochloride As required for pH As required for pH
    Acid, 1N adjustment to 7.3% adjustment to 7.3%
    Sodium As required for pH As required for pH
    Hydroxide, adjustment to 7.3% adjustment to 7.3%
    1N
    Polyoxyl 40 Cremophor  0.1% 0.5 mL of 10%
    Hydrogenated RH 40 from
    Castor Oil BASF Co.
    Purified Water To 98% Dilute to 49 mL
    Sodium Fisher As required for As required for
    Chloride tonicity adjustment tonicity adjustment
    300 mOsm 300 mOsm
    Purified Water Too 100% Dilute to 50 mL

Claims (30)

1. A method for rendering a contact lens wettable by contacting the surface of said lens with an aqueous solution comprising from 0.001 to about 10 percent by weight of an ethoxylated glyceride, 0.001 to 2.0 percent by weight of a physiologically acceptable buffer, 0.00001 to 0.1 weight percent of a polymeric preservative, and the balance water.
2. The method of claim 1 wherein said ethoxylated glyceride is polyoxyl 40 hydrogenated castor oil.
3. The method of claim 1 wherein said ethoxylated glyceride is polyoxyl 60 hydrogenated castor oil.
4. The method of claim 1 wherein said ethoxylated glyceride is chosen from the group consisting of PEG-6 Caprylic/Capric Glycerides PEG-8 Caprylic/Capric Glycerides; PEG-2 Castor Oil; PEG-3 Castor Oil; PEG-4 Castor Oil; PEG-5 Castor Oil; PEG-8 Castor Oil; PEG-9 Castor Oil; PEG-10 Castor Oil; PEG-11 Castor Oil; PEG-15 Castor Oil; PEG-20 Castor Oil; PEG-25 Castor Oil; PEG-30 Castor Oil; PEG-33 Castor Oil; PEG-35 Castor Oil; PEG-36 Castor Oil; PEG-40 Castor Oil; PEG-50 Castor Oil; PEG-54 Castor Oil; PEG-55 Castor Oil; PEG-60 Castor Oil; PEG-100 Castor Oil; PEG-200 Castor Oil; PEG-18 Castor Oil Dioleate; PEG-60 Corn Glycerides; PEG-20 Evening Primrose Glycerides; PEG-60 Evening Primrose Glycerides; PEG-7 Glyceryl Cocoate; PEG-30 Glyceryl Cocoate; PEG-78 Glyceryl Cocoate; PEG-80 Glyceryl Cocoate; PEG-12 Glyceryl Dioleate; PEG-15 Glyceryl Isostearate; PEG-20 Glyceryl Isostearate; PEG-30 Glyceryl Isostearate; PEG-60 Glyceryl Isostearate; PEG-12 Glyceryl Laurate; PEG-20 Glyceryl Laurate; PEG-23 Glyceryl Laurate; PEG-30 Glyceryl Laurate; PEG-10 Glyceryl Oleate; PEG-15 Glyceryl Oleate; PEG-30 Glyceryl Oleate; PEG-20 Glyceryl Ricinoleate; PEG-5 Glyceryl Sesquioleate; PEG-5 Glyceryl Stearate; PEG-10 Glyceryl Stearate; PEG-25 Glyceryl Stearate; PEG-30 Glyceryl Stearate; PEG-120 Glyceryl Stearate; PEG-200 Glyceryl Stearate; PEG-28 Glyceryl Tallowate; PEG-80 Glyceryl Tallowate; PEG-200 Glyceryl Tallowate; PEG-5 Glyceryl Triisostearate; PEG-5 Hydrogenated Castor Oil; PEG-7 Hydrogenated Castor Oil; PEG-16 Hydrogenated Castor Oil; PEG-20 Hydrogenated Castor Oil; PEG-25 Hydrogenate Castor Oil; PEG-30 Hydrogenate Castor Oil; PEG-35 Hydrogenate Castor Oil; PEG-40 Hydrogenate Castor Oil; PEG-45 Hydrogenate Castor Oil; PEG-50 Hydrogenate Castor Oil; PEG-54 Hydrogenate Castor Oil; PEG-55 Hydrogenate Castor Oil; PEG-60 Hydrogenate Castor Oil; PEG-80 Hydrogenate Castor Oil; PEG-100 Hydrogenate Castor Oil; PEG-200 Hydrogenate Castor Oil; PEG-40 Hydrogenated Castor Oil PCA Isosterate; PEG-5 Hydrogenated Corn Glycerides; and PEG-8 Hydrogenated Fish Glycerides.
5. The method of claim 1 wherein said ethoxylated glyceride is polyoxyl 35 castor oil.
6. The method of claim 1 wherein said buffer is selected from the group consisting of bis(2-hydroxyethyl)iminotris(hydroxymethyl)methane and its salts.
7. The method of claim 1 wherein said buffer is selected from the group consisting of 1,3-bis[tris(hydroxymethyl)-methylamino]propane and its salts.
8. The method of claim 1 wherein said buffer is selected from the group consisting of N-tris(hydroxymethyl) methyl glycine and its salts.
9. The method of claim 1 wherein said buffer is selected from the group consisting of N,N-bis(2-hydroxyethyl)-glycine and its salts.
10. The method of claim 1 wherein said buffer is selected from the group consisting of betaine and its salts.
11. The method of claim 1 wherein said buffer is a phosphate salt.
12. The method of claim 1 wherein said buffer is a borate salt.
13. The method of claim 1 wherein said buffer is a citrate salt.
14. The method of claim 1 wherein said buffer is selected from the group consisting of 2-amino-2-methyl-1,3-propanediol and its salts.
15. The method of claim 1 wherein said buffer is selected from the group consisting of triisopropanolamine and its salts.
16. The method of claim 1 wherein said buffer is selected from the group consisting of camitine and its salts.
17. The method of claim 1 wherein said buffer is selected from the group consisting of dimethyl glutamate and its salts.
18. The method of claim 1 wherein said buffer is selected from the group consisting of diethanolamine and its salts.
19. The method of claim 1 wherein said buffer is selected from the group consisting of diisopropylamine and its salts.
20. The method of claim 1 wherein said buffer is selected from the group consisting of triethanolamine and its salts.
21. The method of claim 1 wherein said buffer is selected from the group consisting of triethylamine and its salts.
22. The method of claim 1 wherein said buffer is selected from the group consisting of imidazole and its salts.
23. The method of claim 1 wherein said buffer is selected from the group consisting of histidine and its salts.
24. The method of claim 1 wherein said buffer is selected from the group consisting of methyl aspartate and its salts.
25. The method of claim 1 wherein said buffer is selected from the group consisting of Tris(hydroxymethyl)aminomethane and its salts.
26. The method of claim 1 wherein said buffer is selected from the group consisting of glycine and its salts.
27. The method of claim 1 wherein said buffer is selected from the group consisting of lysine and its salts.
28. The method of claim 1 wherein said polymeric preservative is polyhexamethylene biguanide.
29. The method of claim 1 wherein said aqueous solution is a contact lens wetting solution.
30. The method of claim 1 wherein said aqueous solution is a contact lens rinsing solution.
US13/327,295 1999-11-04 2011-12-15 Ophthalmic and contact lens solution Abandoned US20120083534A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/327,295 US20120083534A1 (en) 1999-11-04 2011-12-15 Ophthalmic and contact lens solution

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16345599P 1999-11-04 1999-11-04
US70633800A 2000-11-04 2000-11-04
US10/842,162 US7678836B2 (en) 1999-11-04 2004-05-10 Method for rendering a contact lens wettable
US12/693,878 US8247461B2 (en) 1999-11-04 2010-01-26 Ophthalmic and contact lens solution
US13/327,295 US20120083534A1 (en) 1999-11-04 2011-12-15 Ophthalmic and contact lens solution

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12/693,878 Continuation US8247461B2 (en) 1999-11-04 2010-01-26 Ophthalmic and contact lens solution

Publications (1)

Publication Number Publication Date
US20120083534A1 true US20120083534A1 (en) 2012-04-05

Family

ID=46302044

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/842,162 Expired - Lifetime US7678836B2 (en) 1999-11-04 2004-05-10 Method for rendering a contact lens wettable
US12/693,878 Expired - Fee Related US8247461B2 (en) 1999-11-04 2010-01-26 Ophthalmic and contact lens solution
US13/327,295 Abandoned US20120083534A1 (en) 1999-11-04 2011-12-15 Ophthalmic and contact lens solution

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US10/842,162 Expired - Lifetime US7678836B2 (en) 1999-11-04 2004-05-10 Method for rendering a contact lens wettable
US12/693,878 Expired - Fee Related US8247461B2 (en) 1999-11-04 2010-01-26 Ophthalmic and contact lens solution

Country Status (1)

Country Link
US (3) US7678836B2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109453146A (en) * 2018-12-27 2019-03-12 佛山市南海东方澳龙制药有限公司 Composition of resisting pathogenic microbes and its preparation method and application
US11000475B2 (en) * 2015-10-16 2021-05-11 Sun Pharma Advanced Research Company Limited Ophthalmic solution of difluprednate

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678836B2 (en) * 1999-11-04 2010-03-16 Fxs Ventures, Llc Method for rendering a contact lens wettable
US8557868B2 (en) 2000-11-04 2013-10-15 Fxs Ventures, Llc Ophthalmic and contact lens solutions using low molecular weight amines
US20060148665A1 (en) * 2000-11-08 2006-07-06 Bioconcept Laboratories Ophthalmic and contact lens solutions containing forms of vitamin b
US20070110782A1 (en) * 2000-11-08 2007-05-17 Fxs Ventures, Llc L-histidine in ophthalmic solutions
US9492582B2 (en) * 2000-11-08 2016-11-15 Fxs Ventures, Llc Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
CA2428994C (en) * 2000-11-08 2010-05-11 Bio-Concept Laboratories Improved ophthalmic and contact lens solutions containing forms of vitamin b
US20070104744A1 (en) * 2000-11-08 2007-05-10 Fxs Ventures, Llc Ophthalmic and contact lens solutions containing forms of vitamin b
CN1245166C (en) * 2000-11-08 2006-03-15 生物概念实验室 Improved ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
US20070098813A1 (en) * 2000-11-08 2007-05-03 Fxs Ventures, Llc Ophthalmic and contact lens solutions with a peroxide source and a preservative
US9308264B2 (en) 2000-11-08 2016-04-12 Fxs Ventures, Llc Ophthalmic contact lens solutions containing forms of vitamin B
US20060127496A1 (en) * 2000-11-08 2006-06-15 Bioconcept Laboratories L-histidine in ophthalmic solutions
JP2006505132A (en) * 2002-11-05 2006-02-09 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング Semiconductor surface treatment and compounds used in it
WO2004091438A2 (en) * 2003-04-15 2004-10-28 Fxs Ventures, Llc Improved ophthalmic and contact lens solutions containing peptides as representative enhancers
DK1656955T3 (en) * 2003-08-20 2007-12-27 Menicon Co Ltd Liquid composition for a contact lens
US8534031B2 (en) * 2008-12-30 2013-09-17 Bausch & Lomb Incorporated Packaging solutions
CN101756900B (en) * 2010-02-25 2012-05-30 谢恬 Elemene microemulsion
US8980839B2 (en) 2012-08-24 2015-03-17 Ocular Technologies Sarl Topical aqueous nanomicellar, ophthalmic solutions and uses thereof
CN106794254A (en) * 2014-05-23 2017-05-31 视觉技术有限责任公司 Topical formulations and its application
DK3373976T3 (en) 2015-11-10 2024-04-02 Sun Pharmaceutical Ind Ltd TOPICAL FORMULATIONS AND USES THEREOF
US10918694B2 (en) 2016-02-29 2021-02-16 Sun Pharma Global Fze Topical cyclosporine-containing formulations and uses thereof

Citations (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0180309A1 (en) * 1984-09-28 1986-05-07 BAUSCH & LOMB INCORPORATED Improved disinfecting and preserving solutions for contact lenses and methods of use
US4836986A (en) * 1984-09-28 1989-06-06 Bausch & Lomb Incorporated Disinfecting and preserving systems and methods of use
US4908147A (en) * 1986-02-19 1990-03-13 Ciba-Geigy Corporation Aqueous self preserving soft contact lens solution and method
US4960799A (en) * 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
US5246552A (en) * 1989-09-21 1993-09-21 Tomei Sangyo Kabushiki Kaisha Method for cleaning and disinfecting soft contact lens and treating solution for soft contact lenses
WO1994015649A1 (en) * 1993-01-07 1994-07-21 Polymer Technology Corporation Preservative system for contact lens solutions
US5389383A (en) * 1993-06-18 1995-02-14 Allergan, Inc. Method for treating hypoxia-associated ocular complications
WO1995030414A1 (en) * 1994-05-06 1995-11-16 Smith Francis X An improved ocular care solution
US5576028A (en) * 1988-08-04 1996-11-19 Ciba Geigy Corporation Method of preserving ophthalmic solutions and compositions therefor
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5653972A (en) * 1994-11-16 1997-08-05 Alcon Laboratories, Inc. Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
US5686488A (en) * 1995-08-25 1997-11-11 Alcon Laboratories, Inc. Polyethoxylated castor oil products as anti-inflammatory agents
EP0836111A1 (en) * 1996-03-29 1998-04-15 Tomey Technology Corporation Contact lens cleaning solution and method for cleaning contact lenses using the same
US5756045A (en) * 1990-12-27 1998-05-26 Allergan Method and composition for disinfecting contact lenses
EP0888780A1 (en) * 1996-11-13 1999-01-07 Tomey Technology Corporation Treatment composition for contact lenses and method for treating contact lenses with the same
US5891913A (en) * 1994-10-10 1999-04-06 Novartis Finance Corporation Ophthalmic and aural compositions containing diclofenac potassium
EP0915151A1 (en) * 1997-11-10 1999-05-12 Tomey Corporation Method of cleaning and disinfecting contact lenses
US5922279A (en) * 1996-02-28 1999-07-13 Bausch & Lomb Incorporated Treatment of contact lenses with an aqueous solution including pyrrolidone compounds
EP0938903A1 (en) * 1996-02-07 1999-09-01 Rohto Pharmaceutical Co., Ltd. Ophthalmic composition with regulated viscosity
EP0947203A2 (en) * 1998-03-27 1999-10-06 Menicon Co., Ltd. Agent for contact lenses
US6121327A (en) * 1998-05-22 2000-09-19 Menicon Co., Ltd. Contact lens disinfecting solution
US6162393A (en) * 1998-08-06 2000-12-19 Ndt, Inc. Contact lens and ophthalmic solutions
US6482799B1 (en) * 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
US6565894B1 (en) * 1999-11-05 2003-05-20 Francis X. Smith Healthcare formulations comprising imidazole and hydrogen peroxide
US6617291B1 (en) * 2001-11-08 2003-09-09 Francis X. Smith Ophthalmic and contact lens solutions
US6624203B1 (en) * 2001-11-08 2003-09-23 Francis X. Smith Nucleic acid bases used in ophthalmic solutions
US7678836B2 (en) * 1999-11-04 2010-03-16 Fxs Ventures, Llc Method for rendering a contact lens wettable

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US32672A (en) * 1861-07-02 Manjsr
US1432345A (en) * 1920-09-15 1922-10-17 Powers Accounting Machine Comp Rotary selector or analyzer
US2976576A (en) * 1956-04-24 1961-03-28 Wichterle Otto Process for producing shaped articles from three-dimensional hydrophilic high polymers
US2925317A (en) * 1956-09-18 1960-02-16 Joseph E Moore Shrinkproofing of protein fibers with polyalkyleneimines
US3429576A (en) * 1965-08-28 1969-02-25 Yoshiaki Ikeda Golf club having level indicating means and weight means
GB1152243A (en) * 1965-11-26 1969-05-14 Ici Ltd Process for the Manufacture of Polymeric Diguanides
US3503393A (en) * 1966-05-19 1970-03-31 Blease Anaesthetic Equip Ltd Patient controlled respiratory apparatus
GB1167285A (en) * 1967-03-15 1969-10-15 Ceskoslovenska Akademie Ved Method of Preserving Hydrophilic Gels
US3689673A (en) * 1970-11-10 1972-09-05 Barnes Hind Pharm Inc The process of soaking and sterilizing hydrophilic soft contact lenses with chlorhexidene
US3755561A (en) * 1971-03-22 1973-08-28 Burton Parsons & Co Inc Bactericidal contact lens solution
CH564947A5 (en) * 1971-06-21 1975-08-15 Wave Energy Systems
US3873696A (en) * 1972-01-31 1975-03-25 Allergan Pharma Cleaning and sterilizing soft contact lens
NO135634C (en) 1972-03-16 1977-05-04 Farmaceutisk Ind As
US4022834A (en) * 1972-03-16 1977-05-10 A/S Farmaceutisk Industri Antibacterially active hexamethylene-bis-biguanides
US3888782A (en) * 1972-05-08 1975-06-10 Allergan Pharma Soft contact lens preserving solution
US3876768A (en) * 1972-11-06 1975-04-08 Hydrophilics Int Inc Sterilization of soft, hydrophilic acrylate and methacrylate copolymer materials
US3911107A (en) * 1972-12-18 1975-10-07 Flow Pharma Inc Iodine composition and dissipating solution
US4136185A (en) * 1972-12-23 1979-01-23 Boehringer Ingelheim Gmbh N-Aryl-N'-(phenyl-or phenoxy-alkyl)-piperazines and salts thereof
US3910296A (en) * 1973-04-20 1975-10-07 Allergan Pharma Method of removing proteinaceous deposits from contact lenses
US3943251A (en) * 1973-06-27 1976-03-09 Medow Norman B Ophthamological use of hydrastis compounds
US4029817A (en) * 1973-09-24 1977-06-14 Allergan Pharmaceuticals Soft contact lens preserving solutions
GB1562899A (en) * 1975-06-17 1980-03-19 Wellcome Found Pharmaceutical compositions containing substituted 9-( -d-arabnofuranosyl)purine-5'-phosphate and salts thereof
US4046706A (en) * 1976-04-06 1977-09-06 Flow Pharmaceuticals, Inc. Contact lens cleaning composition
IT1063325B (en) * 1976-05-19 1985-02-11 Brevitex Ets Exploit DEVICE FOR SPREADING THE CROSSBODY FRAMES
US4136173A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Mixed xanthan gum and locust beam gum therapeutic compositions
JPS5486887A (en) * 1977-12-22 1979-07-10 Toyoda Mach Works Ltd Numerical controller
US4209817A (en) * 1978-03-15 1980-06-24 Square D Company Circuit breaker having an electronic fault sensing and trip initiating unit
US4394381A (en) * 1979-04-13 1983-07-19 George F. And Irene Sherrill 1978 Trust No. 1 Method for the relief of pain
US4361549A (en) * 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
JPS599600B2 (en) * 1980-11-14 1984-03-03 花王株式会社 Shampoo - Composition
US4361548A (en) * 1980-11-28 1982-11-30 Bausch & Lomb Incorporated Contact lens disinfecting and preserving solution (polymeric)
US4361458A (en) * 1981-02-13 1982-11-30 The Wurlitzer Company Piano soundboard and method of making same
US4354952A (en) * 1981-03-12 1982-10-19 Bausch & Lomb Incorporated Contact lens disinfecting and preserving solution comprising chlorhexidine and salts thereof
JPS5840517A (en) 1981-09-03 1983-03-09 Canon Inc Optical device having variable magnification
US4525346A (en) * 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4820352A (en) * 1983-01-10 1989-04-11 Bausch & Lomb Incorporated Cleaning and conditioning solutions for contact lenses and methods of use
JPS6038323A (en) * 1983-08-10 1985-02-27 Sankyo Co Ltd Ophthalmic anti-inflammatory agent
US4758595A (en) * 1984-12-11 1988-07-19 Bausch & Lomb Incorporated Disinfecting and preserving systems and methods of use
US4748189A (en) * 1985-04-19 1988-05-31 Ciba-Geigy Corporation Ophthalmic solutions and methods for improving the comfort and safety of contact lenses
USRE32672E (en) * 1985-09-09 1988-05-24 Allergan, Inc. Method for simultaneously cleaning and disinfecting contact lenses using a mixture of peroxide and proteolytic enzyme
JPH0696521B2 (en) * 1986-01-31 1994-11-30 千寿製薬株式会社 Ocular hypotensive agent for topical ocular administration
JPH0672866B2 (en) * 1986-03-19 1994-09-14 本田技研工業株式会社 Oxygen concentration detector
JPH01104047A (en) 1986-08-07 1989-04-21 Medice Chem Pharm Fab Puetter Gmbh & Co Kg Medicine
US4863900A (en) * 1987-01-15 1989-09-05 The Research Foundation Of State University Of New York Method for reducing viral transmission with poly-L-histidine
US4783488A (en) * 1987-01-31 1988-11-08 Bausch & Lomb Incorporated Contact lens wetting solution
US5246708A (en) * 1987-10-28 1993-09-21 Pro-Neuron, Inc. Methods for promoting wound healing with deoxyribonucleosides
US5624958A (en) * 1987-12-31 1997-04-29 Isaacs; Charles E. Disinfecting contact lenses
US5192535A (en) * 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
JPH01211595A (en) * 1988-02-18 1989-08-24 Kikkoman Corp Novel n-acetyl-beta-d-glucosamine derivative, production thereof and utilization thereof to reagent for measuring n-acetyl-beta-d-glucosamidase activity
US5089261A (en) * 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US4891423A (en) * 1989-03-20 1990-01-02 Stockel Richard F Polymeric biguanides
US5182258A (en) * 1989-03-20 1993-01-26 Orbon Corporation Systemic delivery of polypeptides through the eye
US5175161A (en) * 1989-04-06 1992-12-29 Sankyo Company, Limited Occular hypotensive agents
JP2893537B2 (en) * 1989-07-20 1999-05-24 東海電化工業株式会社 Histidine-hydrogen peroxide adduct and method for producing the same
US4988710A (en) * 1989-08-25 1991-01-29 Washington University Aryl-cycloalkyl-alkanolamines for treatment of cholinergic neurotoxins
US4997626A (en) * 1990-01-05 1991-03-05 Allergan, Inc. Methods to disinfect contact lenses
US5078908A (en) * 1989-10-02 1992-01-07 Allergan, Inc. Methods for generating chlorine dioxide and compositions for disinfecting
US5279673A (en) * 1990-01-05 1994-01-18 Allergan, Inc. Methods to disinfect contact lenses
US5300296A (en) * 1989-11-06 1994-04-05 Frank J. Holly Antimicrobial agent for opthalmic formulations
GB9002422D0 (en) * 1990-02-03 1990-04-04 Boots Co Plc Anti-microbial compositions
US5174872A (en) * 1990-06-08 1992-12-29 Technicon Instruments Corporation Metal-free buffer for ion selective electrode-based assays
US5102670A (en) * 1990-09-14 1992-04-07 Abraham Nader G Method for treating eye disorders by reducing 12(r)-hydroxyeicosatetraenoic acid and 12(r)-dihydroxyeicosatrienoic acid levels
EP0563250A1 (en) 1990-12-19 1993-10-06 Allergan, Inc. Compositions and methods for contact lens disinfecting
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5439572A (en) * 1991-12-02 1995-08-08 Isoclear, Inc. Lens protective encasement packet
WO1994021774A1 (en) * 1993-03-18 1994-09-29 Polymer Technology Corporation Alcohol-containing abrasive composition for cleaning contact lenses
DE4345199C2 (en) * 1993-05-22 1995-10-12 Asta Medica Ag Use of dihydrolipoic acid to suppress intolerance reactions in the border area of implants with living body tissue
ATE168530T1 (en) * 1993-05-26 1998-08-15 Fresenius Ag ANTI-INFECTIVE
US5561107A (en) 1993-06-04 1996-10-01 Demeter Biotechnologies, Ltd. Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides
US5968904A (en) * 1993-06-04 1999-10-19 Demegen, Inc. Modified arginine containing lytic peptides and method of making the same by glyoxylation
US5401327A (en) * 1993-06-18 1995-03-28 Wilmington Partners L.P. Method of treating contact lenses
US5661130A (en) * 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
US5449658A (en) * 1993-12-07 1995-09-12 Zeneca, Inc. Biocidal compositions comprising polyhexamethylene biguanide and EDTA, and methods for treating commercial and recreational water
JPH07169807A (en) * 1993-12-16 1995-07-04 Nippondenso Co Ltd Semiconductor wafer
US5591773A (en) * 1994-03-14 1997-01-07 The Trustees Of Columbia University In The City Of New York Inhibition of cataract formation, diseases resulting from oxidative stress, and HIV replication by caffeic acid esters
CA2185699A1 (en) * 1994-04-04 1995-10-12 William R. Freeman Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure
US5674450A (en) * 1994-04-28 1997-10-07 Johnson & Johnson Medical, Inc. Vapor sterilization using a non-aqueous source of hydrogen peroxide
US5547990A (en) * 1994-05-20 1996-08-20 Lonza, Inc. Disinfectants and sanitizers with reduced eye irritation potential
WO1996003158A1 (en) * 1994-07-22 1996-02-08 Alcon Laboratories, Inc. Use of low molecular weight amino acids in ophthalmic compositions
US5494937A (en) * 1994-07-22 1996-02-27 Alcon Laboratories, Inc. Saline solution for treating contact lenses
US5530288A (en) * 1994-10-12 1996-06-25 International Business Machines Corporation Passive interposer including at least one passive electronic component
ES2278566T3 (en) * 1994-10-20 2007-08-16 Sysmex Corporation REAGENT AND METHOD FOR ANALYZING SOLID COMPONENTS IN THE URINE.
US5739178A (en) 1995-05-15 1998-04-14 Allergan Polymer, article and method for inhibiting the growth of ocular pathogens in eye care products
US5969538A (en) * 1996-10-31 1999-10-19 Texas Instruments Incorporated Semiconductor wafer with interconnect between dies for testing and a process of testing
US5718895A (en) * 1995-11-16 1998-02-17 Alcon Laboratories, Inc. Enzymes with low isoelectric points for use in contact lens cleaning
US5780450A (en) * 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
US5965736A (en) * 1996-01-16 1999-10-12 Lumigen, Inc. Compositions and methods for generating red chemiluminescence
WO1997026923A1 (en) * 1996-01-22 1997-07-31 Bausch & Lomb Incorporated Dual neutralization system for iodine treatment of contact lenses
JP2000513209A (en) 1996-02-16 2000-10-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Antimicrobial peptides and methods of use
JPH1070243A (en) * 1996-05-30 1998-03-10 Toshiba Corp Semiconductor integrated circuit device, its inspection method and its inspection device
US6358897B1 (en) * 1996-06-07 2002-03-19 Alcon Laboratories, Inc. Alkyl trypsin compositions and methods of use in contact lens cleaning and disinfecting systems
JPH1059846A (en) 1996-06-10 1998-03-03 Kikkoman Corp Preventive or remedy for cararacta
US5800656A (en) * 1996-07-01 1998-09-01 Avery Dennison Corporation Heat-transfer label including phenoxy protective lacquer layer
US5719110A (en) * 1996-08-14 1998-02-17 Allergan Contact lens care compositions with inositol phosphate components
JP3698832B2 (en) 1996-10-08 2005-09-21 株式会社メニコン Contact lens solution
JP3829380B2 (en) * 1996-12-18 2006-10-04 住友化学株式会社 Pest repellent and pest repellent method
US5952320A (en) 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
US5945446A (en) * 1997-02-10 1999-08-31 Laubc Biochemicals, Corporation Process for preparing synthetic soil-extract materials and medicaments based thereon
US6022732A (en) * 1997-04-09 2000-02-08 Allergan Hydrogen peroxide destroying compositions and methods of using same
RU2127100C1 (en) 1997-04-17 1999-03-10 Борзенок Сергей Анатольевич Ocular drops "pyrotonik"
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US5925320A (en) * 1997-06-04 1999-07-20 Jones; John P. Air purification system
EP1030692B1 (en) * 1997-11-12 2002-07-10 Bausch & Lomb Incorporated Treatment of contact lenses with aqueous solution comprising an alkali carbonate
BR9814012A (en) * 1997-11-12 2000-09-26 Bausch & Lomb Disinfection of contact lenses with polyquaterniums and polymeric biguanides.
US6056920A (en) * 1997-12-12 2000-05-02 Vertex Pharmaceuticals Incorporated Process for identifying a solvent condition suitable for determining a biophysical property of a protein
JPH11249087A (en) 1997-12-18 1999-09-17 Tome:Kk Light agent for contact lens
KR100283030B1 (en) * 1997-12-31 2001-03-02 윤종용 Layout structure of semiconductor device
RU2127106C1 (en) * 1998-03-16 1999-03-10 Суханов Александр Иванович Cholelithiasis treatment method
US6162398A (en) 1998-04-16 2000-12-19 Becton Dickinson And Company Assay device using shrink wrap
JP2000016965A (en) 1998-06-29 2000-01-18 Mitsubishi Gas Chem Co Inc Process for producing caprolactone-modified hydroxyalkyl acrylate or methacrylate
US6117869A (en) * 1998-08-04 2000-09-12 Warner-Lambert Company Compounds for and methods of inhibiting matrix metalloproteinases
EP1026539A4 (en) * 1998-08-21 2003-06-25 Senju Pharma Co Compositions for contact lenses
US6233184B1 (en) * 1998-11-13 2001-05-15 International Business Machines Corporation Structures for wafer level test and burn-in
US6309596B1 (en) * 1998-12-15 2001-10-30 Bausch & Lomb Incorporated Treatment of contact lenses with aqueous solution comprising a biguanide disinfectant stabilized by a poloxamine
US6211050B1 (en) * 1999-03-03 2001-04-03 Chartered Semiconductor Manufacturing Ltd. Fill pattern in kerf areas to prevent localized non-uniformities of insulating layers at die corners on semiconductor substrates
JP2001135597A (en) * 1999-08-26 2001-05-18 Fujitsu Ltd Method for manufacturing semiconductor device
US8557868B2 (en) * 2000-11-04 2013-10-15 Fxs Ventures, Llc Ophthalmic and contact lens solutions using low molecular weight amines
US6550862B2 (en) * 2001-06-14 2003-04-22 Cosco Management, Inc. Juvenile vehicle seat cup holder

Patent Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0180309A1 (en) * 1984-09-28 1986-05-07 BAUSCH & LOMB INCORPORATED Improved disinfecting and preserving solutions for contact lenses and methods of use
US4836986A (en) * 1984-09-28 1989-06-06 Bausch & Lomb Incorporated Disinfecting and preserving systems and methods of use
US4908147A (en) * 1986-02-19 1990-03-13 Ciba-Geigy Corporation Aqueous self preserving soft contact lens solution and method
US5576028A (en) * 1988-08-04 1996-11-19 Ciba Geigy Corporation Method of preserving ophthalmic solutions and compositions therefor
US4960799A (en) * 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
US5246552A (en) * 1989-09-21 1993-09-21 Tomei Sangyo Kabushiki Kaisha Method for cleaning and disinfecting soft contact lens and treating solution for soft contact lenses
US5756045A (en) * 1990-12-27 1998-05-26 Allergan Method and composition for disinfecting contact lenses
US5453435A (en) * 1993-01-07 1995-09-26 Polymer Technology Corporation Preservative system for contact lens solutions
WO1994015649A1 (en) * 1993-01-07 1994-07-21 Polymer Technology Corporation Preservative system for contact lens solutions
US5389383A (en) * 1993-06-18 1995-02-14 Allergan, Inc. Method for treating hypoxia-associated ocular complications
WO1995030414A1 (en) * 1994-05-06 1995-11-16 Smith Francis X An improved ocular care solution
US5891913A (en) * 1994-10-10 1999-04-06 Novartis Finance Corporation Ophthalmic and aural compositions containing diclofenac potassium
US5653972A (en) * 1994-11-16 1997-08-05 Alcon Laboratories, Inc. Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5686488A (en) * 1995-08-25 1997-11-11 Alcon Laboratories, Inc. Polyethoxylated castor oil products as anti-inflammatory agents
EP0938903A1 (en) * 1996-02-07 1999-09-01 Rohto Pharmaceutical Co., Ltd. Ophthalmic composition with regulated viscosity
US5922279A (en) * 1996-02-28 1999-07-13 Bausch & Lomb Incorporated Treatment of contact lenses with an aqueous solution including pyrrolidone compounds
EP0836111A1 (en) * 1996-03-29 1998-04-15 Tomey Technology Corporation Contact lens cleaning solution and method for cleaning contact lenses using the same
EP0888780A1 (en) * 1996-11-13 1999-01-07 Tomey Technology Corporation Treatment composition for contact lenses and method for treating contact lenses with the same
EP0915151A1 (en) * 1997-11-10 1999-05-12 Tomey Corporation Method of cleaning and disinfecting contact lenses
US6126706A (en) * 1997-11-10 2000-10-03 Tomey Corporation Method of cleaning and disinfecting contact lens
EP0947203A2 (en) * 1998-03-27 1999-10-06 Menicon Co., Ltd. Agent for contact lenses
US6121327A (en) * 1998-05-22 2000-09-19 Menicon Co., Ltd. Contact lens disinfecting solution
US6162393A (en) * 1998-08-06 2000-12-19 Ndt, Inc. Contact lens and ophthalmic solutions
US6482799B1 (en) * 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
US7678836B2 (en) * 1999-11-04 2010-03-16 Fxs Ventures, Llc Method for rendering a contact lens wettable
US20100122918A1 (en) * 1999-11-04 2010-05-20 Smith Francis X Ophthalmic and contact lens solution
US8247461B2 (en) * 1999-11-04 2012-08-21 Smith Francis X Ophthalmic and contact lens solution
US6565894B1 (en) * 1999-11-05 2003-05-20 Francis X. Smith Healthcare formulations comprising imidazole and hydrogen peroxide
US6617291B1 (en) * 2001-11-08 2003-09-09 Francis X. Smith Ophthalmic and contact lens solutions
US6624203B1 (en) * 2001-11-08 2003-09-23 Francis X. Smith Nucleic acid bases used in ophthalmic solutions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Good et al., "Hydrogen Ion Buffers for Biological Research", Biochemistry, Vol. 5, No. 2, (Feb. 1966), pp. 467-477. *
O'Neil, Maryadele J. et al. (©2006, 2010), The Merck Index-An Encyclopedia of Chemicals, Drugs, and Biologicals (14th Ed.-Vers 14.6), Merck Sharp & Dohme Corp., Whitehouse Station, NJ (Knovel Date: 12/1/2007), Entries "09772.Tromethamine", Online @ http://knovel.com/web/portal/browse/display?_EXT_KNOVEL_DISPLAY_bookid=1863&VerticalID=0, pp. 1-2. *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11000475B2 (en) * 2015-10-16 2021-05-11 Sun Pharma Advanced Research Company Limited Ophthalmic solution of difluprednate
US11103451B2 (en) * 2015-10-16 2021-08-31 Sun Pharma Advanced Research Company Limited Ophthalmic solution of difluprednate
US11890375B2 (en) 2015-10-16 2024-02-06 Sun Pharma Advanced Research Company Limited Ophthalmic solution of difluprednate
US12383496B2 (en) 2015-10-16 2025-08-12 Sun Pharma Advanced Research Company Limited Ophthalmic solution of difluprednate
CN109453146A (en) * 2018-12-27 2019-03-12 佛山市南海东方澳龙制药有限公司 Composition of resisting pathogenic microbes and its preparation method and application

Also Published As

Publication number Publication date
US20050042198A1 (en) 2005-02-24
US7678836B2 (en) 2010-03-16
US20100122918A1 (en) 2010-05-20
US8247461B2 (en) 2012-08-21

Similar Documents

Publication Publication Date Title
US8247461B2 (en) Ophthalmic and contact lens solution
AU2006207883B2 (en) Improved ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
EP1572253B1 (en) Lens care composition and method
EP1337262B1 (en) Improved ophthalmic and contact lens solutions with a peroxide source and a cationic polymeric preservative
US9492582B2 (en) Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
AU2003301080B2 (en) Use of multifunctional surface active agents to clean contact lenses
AU2002227206A1 (en) Improved ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
HU212184B (en) Method and composition for disinfecting contact-lenses
JP2008538823A (en) Borate-polyol mixture as buffer system
US20030133905A1 (en) Composition for treating contact lenses in the eye
US10531663B2 (en) Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
EP1792972A1 (en) Use of multifuctional surface active agents to clean contact lenses
HK1011600B (en) Use of amidoamines in ophthalmic compositions
HK1011600A1 (en) Use of amidoamines in ophthalmic compositions

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION